Advisor Group Holdings, Inc. Unity Biotechnology, Inc. Transaction History

Advisor Group Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.4 - $4.27 $4,420 - $47,183	11,050 Added 38.56%	39,704 $15,000
Q2 2022 Aug 10, 2022	BUY	$0.56 - $1.29 $231 - $532	413 Added 1.46%	28,654 $16,000
Q1 2022 May 04, 2022	BUY	$0.72 - $1.86 $4,492 - $11,606	6,240 Added 28.36%	28,241 $62,000
Q3 2021 Nov 05, 2021	SELL	$2.91 - $4.5 $9,629 - $14,890	-3,309 Reduced 13.07%	22,001 $65,000
Q2 2021 Aug 02, 2021	SELL	$4.15 - $6.3 $49,385 - $74,970	-11,900 Reduced 31.98%	25,310 $116,000
Q1 2021 May 13, 2021	BUY	$5.51 - $9.42 $180,915 - $309,296	32,834 Added 750.32%	37,210 $223,000
Q4 2020 Feb 10, 2021	BUY	$3.42 - $6.36 $3,727 - $6,932	1,090 Added 33.17%	4,376 $23,000
Q3 2020 Nov 12, 2020	SELL	$2.94 - $12.43 $4,292 - $18,147	-1,460 Reduced 30.76%	3,286 $12,000
Q2 2020 Aug 14, 2020	BUY	$5.28 - $9.67 $24,530 - $44,926	4,646 Added 4646.0%	4,746 $41,000
Q1 2020 May 18, 2020	BUY	$5.0 - $7.6 $500 - $760	100 New	100 $1,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $16.1M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.